Infections and Infectious Diseases

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Condition:   Respiratory Syncytial Virus (RSV)
Interventions:   Biological: RSV ΔNS2/Δ1313/I1314L Vaccine;   Biological: RSV 6120/ΔNS2/1030s Vaccine;   Biological: RSV 276 Vaccine;   Biological: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 21, 2019Comments Off6120/ΔNS2/1030s | Children | Delivered | Dose | Drops | Immunogenicity | LiveAttenuated | Months | Nose | Placebo | Recombinant | Respiratory | RSVSeronegative | Safety | Single | Syncytial | Vaccines | Virus | ΔNS2/Δ1313/I1314L
Belimumab With Rituximab for Primary Membranous Nephropathy

Conditions:   Membranous Nephropathy;   MN
Interventions:   Drug: Belimumab;   Drug: Placebo for Belimumab;   Drug: Rituximab
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN);   GlaxoSmithKline
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 20, 2019Comments OffBelimumab | Membranous | Nephropathy | Primary | Rituximab
Immunology of HIV and Alcoholic Hepatitis

Conditions:   HIV/AIDS;   Alcoholic Hepatitis
Interventions:   Other: Alcoholic Hepatitis Group;   Other: Heavy Drinking Controls without Hepatitis
Sponsor:   Indiana University
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 19, 2019Comments OffAlcoholic | Hepatitis | Immunology
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

Condition:   Opioid-Related Disorders
Intervention:   Device: Deep Brain Simulator
Sponsors:   West Virginia University;   National Institute on Drug Abuse (NIDA);   Medtronic
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 18, 2019Comments OffBrain | Deep | Disorder | Feasibility | Novel | Opioid | Refractory | Stimulation | Treatment
Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity

Condition:   Bacterial Vaginoses
Interventions:   Drug: Metronidazole Oral;   Drug: Placebo Oral Tablet
Sponsor:   The University of Texas Medical Branch, Galveston
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 17, 2019Comments OffActive | Bacterial | Infectious | Labor | Morbidity | Prior | Treatment | Vaginosis
The Kentucky Viral Hepatitis Treatment Study

Conditions:   Hepatitis C;   Opioid-Related Disorders;   Injection Drug Use
Intervention:   Drug: Sofosbuvir/velpatasvir (Epclusa®)
Sponsors:   Jennifer Havens;   National Institute on Drug Abuse (NIDA);   National Cancer Institute (NCI);   Gilead Sciences;   University of Kentucky;   Icahn School of Medicine at Mount Sinai;   University of Bristol
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 16, 2019Comments OffHepatitis | Kentucky | Study | Treatment | Viral
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Kidney Transplant Recipients

Conditions:   Cytomegalovirus Infections;   Kidney Transplant Infection
Intervention:   Biological: CMV specific T-cells
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin Program for Advanced Cell Therapy (PACT);   University of Wisconsin School of Medicine and Public Health (UWSMPH);   UW Health
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 15, 2019Comments OffAdult | Against | Cells | DoseEscalation | Evaluating | Kidney | Recipients | Safety | Study | Tolerability | Transplant | ViralSpecific
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

Condition:   Cytomegalovirus Infection
Interventions:   Drug: Letermovir;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 13, 2019Comments OffCell | Cytomegalovirus | Extension | From | Hematopoietic | HSCT | Infection | Letermovir | MK8228040 | Participants | PostTransplant | Prevention | Stem | Transplant
Correlating MicroRNA Changes With Sepsis Outcomes

Condition:   Septicemia
Intervention:   Procedure: Biospecimen Collection
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   National Institute of General Medical Sciences (NIGMS)
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 12, 2019Comments OffChanges | Correlating | microRNA | Outcomes | Sepsis